Xeris Biopharma Holdings
XERS
53 hedge funds and large institutions have $176M invested in Xeris Biopharma Holdings in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 2 closing their positions.
200% more call options, than puts
Call options by funds: $9K | Put options by funds: $3K
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
6% more funds holding
Funds holding: 50 → 53 (+3)
3.78% more ownership
Funds ownership: 62.6% → 66.37% (+3.8%)
9% less capital invested
Capital invested by funds: $193M → $176M (-$16.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.51M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.79M |
| 3 |
Millennium Management
New York
|
+$1.05M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$847K |
| 5 |
State Street
Boston,
Massachusetts
|
+$762K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$2.56M |
| 2 |
DM
Deerfield Management
New York
|
-$800K |
| 3 |
MCM
Moore Capital Management
New York
|
-$562K |
| 4 |
Renaissance Technologies
New York
|
-$225K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$143K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $5K | -$35.3K | -3,145 | -86% |
|
52
Daiwa Securities Group
Tokyo,
Japan
| $2K | – | – | – |
|
|
SO
53
STRS Ohio
Columbus,
Ohio
| $2K | – | – | – |
|
|
54
Renaissance Technologies
New York
| – | -$225K | -19,700 | Closed |
|
|
PCM
55
Prelude Capital Management
New York
| – | -$9K | -757 | Closed |
|
XERS Hedge Fund Activity: Q3 2019 in Review
53 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2019, worth a combined $176M — down 8.7% from $193M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new XERS positions and 2 closed out — a net gain of 3 holders — while 27 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.51M. The largest seller was Bank of New York Mellon, cutting an estimated $2.56M.
- 53 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2019, up from 50 in Q2 2019.
- Funds reported $176M of Xeris Biopharma Holdings stock for Q3 2019, down 8.7% quarter-over-quarter.
- 5 funds opened new Xeris Biopharma Holdings positions in Q3 2019 and 2 closed out, a net change of +3 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2019 was Fidelity Investments, an estimated $7.51M added.
- The largest Xeris Biopharma Holdings seller in Q3 2019 was Bank of New York Mellon, an estimated $2.56M sold.
Based on aggregated 13F filings for Q3 2019.